Pancreatic cancer · 6 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Gemcitabine, Cetuximab, RT Variant #01 | — | R 121 995 | 42d | — | — | — | — | — |
Docetaxel, Gemcitabine, RT Variant #01 | — | R 8 474 | 14d | — | — | — | — | — |
Gemcitabine and RT Variant #09 | — | R 7 106 | 56d | — | 15.7 mo | — | — | 2 |
FOLFIRINOX/modified FOLFIRINOX +/- Chemoradiation Variant #01 | — | R 4 554 | 14d | — | — | — | — | — |
mFOLFIRINOX Variant #04 | — | R 3 740 | 14d | 9.7 mo | — | 22 | R 82 287 PFS proxy | 1 |
mFOLFIRINOX (no folinic acid) Variant #01 | — | R 2 632 | 14d | — | — | — | — | — |
6 of 6 regimens shown